… of oncology across indications including breast cancer, ovarian cancer, nasopharyngeal carcinoma, as … choice of Lenvima (lenvatinib) or Nexavar (sorafenib) monotherapy. For those treated …

… —it could have been sorafenib [Nexavar]. What were the outcomes of … preserve ovarian function as with breast cancer treatment? It’s a great …

… receiving lenvatinib (Lenvima) or sorafenib (Nexavar; 20.6 months). The 24 … , particularly in neuro-oncology and breast cancer. The system delivers robotic-assisted …

… with mantle cell lymphoma. In breast cancer, datopotamab deruxtecan and trastuzumab deruxtecan … overall survival compared to sorafenib (Nexavar) or lenvatinib (Lenvima). The median …

… ponatinib (Iclusig), sorafenib (Nexavar), ceritinib (Zykadia), and … at leptomeningeal disease from breast cancer, lung cancer, and … We are looking at breast cancer, specifically. In our … treat patients with breast cancer and leptomeningeal disease. …

… .2-18.5) with sorafenib (Nexavar) in patients with previously untreated … , including liver, lung, gastric, and breast cancer. This agent is approved in …

… benefit compared with sorafenib (Nexavar) for patients with advanced … low breast cancer (n = 713) and HER2–ultra-low breast cancer (n … –ultra-low metastatic breast cancers may benefit from … -her2-low-metastatic-breast-cancer Trastuzumab deruxtecan significantly …

… in the VRd group).14 Breast Cancer Phase 3 DESTINY-Breast06 Trial … +, in situ hybridization negative) metastatic breast cancer following 1 or more lines … with either lenvatinib or sorafenib (Nexavar; Bayer). The ORR was 36% …

… low or HER2-ultralow breast cancer patients who have … low or HER2-ultralow breast cancer. The designation is … -positive metastatic breast cancer and HER2-low metastatic breast cancer. Elsewhere, … Lenvima or Bayer’s Nexavar. Specifically, patients who …